Draft:Sigtuple.ai: Difference between revisions

From Bharatpedia, an open encyclopedia
(Declining submission: bio - Submission is about a person not yet shown to meet notability guidelines (AFCH 0.9.1))
Line 1: Line 1:
{{AFC submission/draft}}
{{AFC submission|d|bio|u=Hexatron93|ns=118|decliner=Muskit Gergous|declinets=20241030183754|ts=20230708135444}} <!-- Do not remove this line! -->
 
<!-- EDIT BELOW THIS LINE -->
<!-- EDIT BELOW THIS LINE -->


SigTuple is an AI based healthcare startup, which analyses blood, urine, semen, chest X-Rays and retinal scans.<ref name="FORBES">https://www.forbes.com/sites/sindhujabalaji/2017/07/18/mission-critical-four-indian-startups-tackling-early-stage-cancer-screening/?sh=4b41319d5e49</ref>  
SigTuple is an AI based healthcare startup, which analyses blood, urine, semen, chest X-Rays and retinal scans.<ref name="FORBES">https://www.forbes.com/sites/sindhujabalaji/2017/07/18/mission-critical-four-indian-startups-tackling-early-stage-cancer-screening/?sh=4b41319d5e49</ref>


==Background==
==Background==
Line 13: Line 14:


== Final Submission ==
== Final Submission ==
{{AfC submission|||ts=20230708135444|u=Hexatron93|ns=118}}

Revision as of 18:37, 30 October 2024


SigTuple is an AI based healthcare startup, which analyses blood, urine, semen, chest X-Rays and retinal scans.[1]

Background

Rohit Kumar Pandey, Apurv Anand and Tathagato Rai Dastidar founded healthcare startup SigTuple in 2015.[2]It has AI platform called MANTHANA.Currently, the team is working with a leading oncology center in India to determine testing patterns for pre-cancerous and cancerous cells using a complete blood count (CBC) test.[1]

SigTuple’s AI100 is the premier solution for AI-assisted digital pathology.Thyrocare, a staunch believer in leveraging technology to drive quality diagnostics at affordable costs, is in the process of deploying SigTuple AI100 across its laboratories.[3]

Awards

Bengaluru-based SigTuple was given the "Judges' Choice" award at the Google's first Demo Day Asia programme held in Shanghai.[2]

Final Submission